Analysis of platelet apheresis products by treatment group
| . | Placebo (n = 65) . | PEG-rHuMGDF 1 μg/kg (n = 23) . | PEG-rHuMGDF 3 μg/kg (n = 22) . | P . |
|---|---|---|---|---|
| Category of platelet yield, × 10114-150 | ||||
| Less than 3 | 17 (26) | 1 (4) | 0 (0) | |
| 3 up to 6 | 43 (66) | 12 (52) | 0 (0) | |
| 6 up to 9 | 5 (8) | 9 (39) | 4 (18) | < .001 |
| 9 up to 12 | 0 (0) | 0 (0) | 11 (50) | |
| At least 12 | 0 (0) | 1 (4) | 7 (32) | |
| Volume platelet-rich plasma, mL | ||||
| Median | 288 | 422 | 576 | < .001 |
| Range | 163-513 | 227-737 | 446-711 | |
| Platelet concentration, × 109/mL4-151 | ||||
| Median | 1.2 | 1.4 | 2.0 | < .001 |
| Range | 0.56-2.0 | 0.66-2.3 | 1.3-2.8 | |
| Category of platelet concentration, × 109/mL)‡ | ||||
| Less than 1.0 | 6 (9) | 2 (9) | 0 (0) | |
| 1.0-2.1 | 59 (91) | 20 (87) | 15 (68) | < .001 |
| More than 2.1 | 0 (0) | 1 (4) | 7 (32) |
| . | Placebo (n = 65) . | PEG-rHuMGDF 1 μg/kg (n = 23) . | PEG-rHuMGDF 3 μg/kg (n = 22) . | P . |
|---|---|---|---|---|
| Category of platelet yield, × 10114-150 | ||||
| Less than 3 | 17 (26) | 1 (4) | 0 (0) | |
| 3 up to 6 | 43 (66) | 12 (52) | 0 (0) | |
| 6 up to 9 | 5 (8) | 9 (39) | 4 (18) | < .001 |
| 9 up to 12 | 0 (0) | 0 (0) | 11 (50) | |
| At least 12 | 0 (0) | 1 (4) | 7 (32) | |
| Volume platelet-rich plasma, mL | ||||
| Median | 288 | 422 | 576 | < .001 |
| Range | 163-513 | 227-737 | 446-711 | |
| Platelet concentration, × 109/mL4-151 | ||||
| Median | 1.2 | 1.4 | 2.0 | < .001 |
| Range | 0.56-2.0 | 0.66-2.3 | 1.3-2.8 | |
| Category of platelet concentration, × 109/mL)‡ | ||||
| Less than 1.0 | 6 (9) | 2 (9) | 0 (0) | |
| 1.0-2.1 | 59 (91) | 20 (87) | 15 (68) | < .001 |
| More than 2.1 | 0 (0) | 1 (4) | 7 (32) |